PROGRAM
All Times are EST
Program is subject to change
Friday, February 11, 2022
| 7:50 am | Welcome and Overview / Pre-Program Test Philip J. Rosenfeld, MD, PhD; Harry W. Flynn, Jr., MD; and Thomas A. Albini, MD |
| Session I: Genetics, Histopathology, and Imaging in Non-Exudative AMD Moderators: Philip J. Rosenfeld, MD, PhD; Giovanni Gregori, PhD; and Zohar Yehoshua, MD, MHA Panelists: Gregory S. Hageman PhD; James G. Fujimoto, PhD; K. Bailey Freund, MD; Christine A. Curcio, PhD; Ruikang Wang, PhD; Lawrence A. Yannuzzi, MD; Giovanni Staurenghi, MD; and Frank G. Holz, MD |
|
| 8:00 | Chromosome 10q26–driven AMD is Associated with Reduced Expression of HTRA1 in Human RPE Gregory S. Hageman, PhD |
| 8:10 | Ultrahigh Resolution OCT in AMD James G. Fujimoto, PhD |
| 8:20 | How Understanding the Histologic Basis of Retinal Imaging Findings in AMD Can Improve Current and Future Patient Outcomes K. Bailey Freund, MD |
| 8:30 | Histology and Clinical Lifecycle of Hyperreflective Foci: Implications for AMD Outcome Measures Christine A. Curcio, PhD |
| 8:40 | Harnessing Optical Attenuation to Quantify Geographic Atrophy and Detect Hyperreflective Foci Ruikang Wang, PhD |
| 8:50 | Using En Face OCT Imaging to Detect When iRORA is Really cRORA Philip J. Rosenfeld, MD, PhD |
| 9:00 | Detachment of the Retinal Pigment Epithelium: Life Cycle Lawrence A. Yannuzzi, MD |
| 9:10 | Extensive Macular Atrophy with Pseudodrusen: What We Know Giovanni Staurenghi, MD |
| 9:20 | MACUSTAR: Functional Impairment and Structural Features in Intermediate AMD Frank G. Holz, FEBO, FARVO |
| Session II: Predicting Progression of AMD Moderators: Thomas A. Albini, MD; Sander R. Dubovy, MD; and Philip J. Rosenfeld, MD, PhD Panelists: Karl G. Csaky, MD, PhD; Emily Y. Chew, MD; Pearse A. Keane, MD; Ursula Schmidt-Erfurth, MD; and Aaron Y. Lee, MD, MSCI |
|
| 9:30 | The Role of Normal and Low Luminance Quantitative Contrast Sensitivity Function Testing in Predicting AMD Progression Karl G. Csaky, MD, PhD |
| 9:40 | Artificial Intelligence/Machine Learning/Deep Learning for Detecting AMD Features and for Predicting Progression to Late AMD Emily Y. Chew, MD |
| 9:50 | Clinically Applicable Deep-Learning Model for Detection and Quantification of Geographic Atrophy from Optical Coherence Tomography Pearse A. Keane, MD |
| 10:00 | Therapeutic Response Pattern of GA Lesion to Pegcetacoplan Ursula Schmidt-Erfurth, MD |
| 10:10 | Scaling Down and Scaling Up, Building Deep Learning Models for Double Layer Sign Detection Aaron Y. Lee, MD, MSCI |
| Session III: Emerging Therapies for Non-Exudative AMD Moderators: Ninel Z. Gregori, MD; Nicolas A. Yannuzzi, MD; and Raquel Goldhardt, MD Panelists: David S. Boyer, MD; Amir H. Kashani, MD, PhD; Nadia K. Waheed, MD, MPH; Glenn J. Jaffe, MD; Peter K. Kaiser, MD; and Justis P. Ehlers, MD |
|
| 10:20 | Inhibition of Connexin43 for the Treatment of AMD and Diabetic Retinopathy David S. Boyer, MD |
| 10:30 | ReCLAIM-2: Baseline Characteristics Including Planned iRORA to cRORA and Ellipsoid Zone Methodologies Justis P. Ehlers, MD |
| 10:40 | One Year Follow-up in a Phase 1/2a Clinical Trial of an Allogeneic RPE Cell Bioengineered Implant for Advanced Dry Age-Related Macular Degeneration Amir H. Kashani, MD, MPH |
| 10:50 | CFI Supplementing Gene Therapy in GA Clinical Trial Update Nadia K. Waheed, MD, MPH |
| 11:00 | Measurement Parameters and Impact of Foveal Preservation in GA Progression in the GATHER-1 Trial Glenn J. Jaffe, MD |
| 11:10 | Novel OCT Findings Regarding “Nascent GA at Risk” and Directionality of GA Progression in the GATHER-1 Trial Peter K. Kaiser, MD |
| Session IV: C3 Inhibition for the Treatment of Geographic Atrophy Moderators: Harry W. Flynn, Jr., MD; Philip J. Rosenfeld, MD, PhD; and Lawrence J. Singerman, MD Panelists: Ramiro Ribeiro MD, PhD; David R. Lally, MD; Jeffrey S. Heier, MD; Charles C. Wykoff, MD; Usha Chakravarthy, MD; and David S. Boyer, MD |
|
| 11:20 | C3 Inhibition for GA: Background and Rationale Ramiro Ribeiro, MD, PhD |
| 11:30 | DERBY and OAKS Phase 3 Results David R. Lally, MD |
| 11:40 | A Deeper Dive into the DERBY and OAKS Phase 3 Results Jeffrey S. Heier, MD |
| 11:50 | Discussion |
| 12:00 pm | Panel Discussion on Translating the Results of Clinical Trials to the Treatment of Nonexudative AMD in the Clinics Panelists: Pravin U. Dugel, MD; Robyn Guymer MBBS, PhD; SriniVas R. Sadda, MD; Karl G. Csaky MD, PhD; Emily Y. Chew, MD; Ramiro Ribeiro, MD PhD; Frank Holz, MD; Glenn J. Jaffe, MD; Pearse A. Keane, MD; Ursula Schmidt-Erfurth, MD; Nadia K. Waheed, MD; Peter K. Kaiser, MD; and Jeffrey S. Heier, MD |
| Session V: OCT Imaging and Risk Factors for Exudative AMD Moderators: Jorge A. Fortun, MD, PhD; Omer Trivizki, MD, MBA; and Philip J. Rosenfeld, MD, PhD Panelists: SriniVas R. Sadda, MD; David Sarraf, MD; Giuseppe Querques, MD; Usha Chakravarthy, MD; Fenghua Wang, MD; and Nancy Holekamp, MD |
|
| 12:30 | Choriocapillaris and Atrophy Associated with Neovascular AMD SriniVas R. Sadda, MD |
| 12:40 | Subretinal Fluid is Protective in Neovascular AMD: Fact or Fallacy? David Sarraf, MD |
| 12:50 | Non-Exudative Treatment-Naive Type 3 MNV Giuseppe Querques, MD |
| 1:00 | Ocular and Systemic Risk Factors for Progression to Exudation in the EDNA Trial Usha Chakravarthy, MD |
| 1:10 | The Predictable Factors for Recurrence of Polypoidal Choroidal Vasculopathy using OCT Anogiograhpy? Fenghua Wang, MD |
| 1:20 | Home OCT Based Tracking of Neovascular AMD Disease Dynamics and Treatment Response Nancy Holekamp, MD |
| 1:30 | Adjourn until Saturday Feb. 12th at 8:00 am |
Saturday, February 12, 2022
| 7:50 am | Welcome and Overview Philip J. Rosenfeld, MD, PhD; Harry W. Flynn, Jr., MD; and Thomas A. Albini, MD |
| Session VI: Emerging and Current Therapies for Exudative AMD Moderators: Thomas A. Albini, MD; Janet L. Davis, MD; and Jaclyn L. Kovach, MD Panelists: Robert Bhisitkul, MD; Arshad M. Khanani, MD, MA; Jay S. Duker, MD; Andrew A. Moshfeghi, MD, MBA; Allen C. Ho, MD; Thomas A. Ciulla, MD, MBA; David M. Brown, MD; Charles C. Wykoff, MD, PhD; Peter A. Campochiaro, MD; David Eichenbaum, MD; Michael S. Ip, MD; Rahul Khurana, MD; Gemmy Cheung, MBBS, FRCOphth, FAMS, MCI; and Veeral S. Sheth, MD, MBA |
|
| 8:00 | Phase 1 Study of Intravitreal UBX1325: A Novel Agent Against Retinal Cell Senescence in AMD and DME Robert Bhisitkul, MD |
| 8:10 | 6-month Results of a Tyrosine Kinase Inhibitor (Vorolanib) in a Bio-erodible Durasert Implant for Previously Treated Wet AMD: The DAVIO Trial Jay S. Duker, MD |
| 8:20 | Safety and Durability of Intravitreal Sunitinib Malate Depot (GB-102) in Wet Age-Related Macular Degeneration (ALTISSIMO, Phase 2B) Veeral S. Sheth, MD, MBA |
| 8:30 | Update on OTX-TKI Clinical Trials for Macular Disease Andrew A. Moshfeghi, MD, MBA |
| 8:40 | OPT-302 Combination Therapy with Ranibizumab for Treatment of Polypoidal Choroidal Vasculopathy Gemmy Cheung MBBS, FRCOphth, FAMS, MCI |
| 8:50 | Update on 4D-150: Inhibition of VEGF A, B, C and PlGF Using Intravitreal, Dual Transgene AAV Gene Therapy for Neovascular AMD Arshad M. Khanani, MD, MA |
| 9:00 | RGX-314 Gene Therapy for Wet AMD Allen C. Ho, MD |
| 9:10 | The Suprachoroidal Space and Suprachoroidal Delivery for Clinicians Thomas A. Ciulla, MD, MBA |
| 9:20 | Update on the AAVIATE Phase 2 Study: Suprachoroidal RGX-314 in Neovascular AMD Rahul N. Khurana, MD |
| 9:30 | CANDELA: High Dose Aflibercept for Neovascular AMD David M. Brown, MD |
| Ranibizumab Port Delivery System | |
| 9:40 | 2-Year Outcomes from the Phase 3 Archway Trial: Management of Neovascular Age-Related Macular Degeneration using the Ranibizumab Port Delivery System Charles C. Wykoff, MD, PhD |
| 9:48 | Long Term (3+ Year) Safety and Efficacy Data for the Port Delivery System David Eichenbaum, MD |
| 9:56 | Patient Level Analysis of the PDS versus Monthly Injections in Neovascular AMD Peter A. Campochiaro, MD |
| 10:04 | Discussion of Previous PDS Talks |
| 10:10 | A Treatment-Agnostic Analysis of the Long-Term Impact of IRF and SRF on Vision and Anatomy in Neovascular AMD in the HAWK and HARRIER Studies Michael S. Ip, MD |
| Session VII: Dual Inhibition of Ang2 and VEGF for the Treatment of Exudative AMD and DME–An Update from the Faricimab Program Moderators: Philip J. Rosenfeld, MD, PhD; Lawrence J. Singerman, MD; and Harry W. Flynn, Jr., MD Panelists: Jeffrey S. Heier, MD; Robyn Guymer, MBBS, PhD; John A. Wells, III, MD; Thomas A. Albini, MD; Jennifer Sun, MD; Arshad Khanani, MD; and Usha Chakravarthy, MD |
|
| 10:20 | Overview of Faricimab for Exudative Retinal Diseases: nAMD, DME, and RVO Jeffrey S. Heier, MD |
| 10:25 | Faricimab Update in nAMD Robyn Guymer, MBBS, PhD |
| 10:30 | Faricimab in DME: 2 Year Data of the Yosemite/Rhine Phase 3 Studies John A. Wells, III, MD |
| 10:40 | Discussion |
| Session VIII: Diabetic Retinopathy-Imaging and Staging Moderators: Justin H. Townsend, MD; Harry W. Flynn, Jr. MD; and Philip J. Rosenfeld, MD, PhD Panelists: Seung-Young Yu, MD; Jennifer Sun, MD; Anat Loewenstein, MD; Ramin Tadayoni, MD, PhD; and Jonathan F. Russell, MD, PhD |
|
| 10:50 | OCT Angiography in Diabetic Retinopathy Harry W. Flynn, Jr., MD |
| 11:00 | SS-OCTA Imaging for Determining Severity of Diabetic Retinopathy Seung-Young Yu, MD |
| 11:10 | Can Capillary Non-Perfusion on OCTA Be a Substitute for Color Photographs in DR Classification? Ramin Tadayoni, MD, PhD |
| 11:20 | Toward a New Staging System for Diabetic Retinopathy Using Widefield Swept-Source Optical Coherence Tomography Angiography Jonathan F. Russell, MD, PhD |
| 11:30 | Detection of Diabetic Retinopathy from Ultra-Wide Field Scanning Laser Ophthalmoscope Images: A Multi-Center Deep-Learning Analysis Anat Loewenstein, MD |
| 11:40 | Updating the Diabetic Retinal Disease Staging System Jennifer Sun, MD |
| Session IX: Diabetic Retinopathy-Treatment Moderators: Harry W. Flynn, Jr., MD; Jayanth Sridhar, MD; and William E. Smiddy, MD Panelists: Michael A. Klufas, MD; Diana V. Do, MD; Mark R. Barakat, MD; Carl D. Regillo, MD; Arshad M. Khanani, MD, MA; Peter K. Kaiser, MD; and Toshinori Murata, MD, PhD |
|
| 11:50 | APX3330, a Phase 2 Oral Drug Inhibiting Novel Target Ref-1 with a Dual Anti-VEGF and Anti-inflammatory MOA for the Treatment of Diabetic Retinal Diseases Peter K. Kaiser, MD |
| 12:00 pm | Phase 2 Results of THR-149 in Patients with DME: KALAHARI Study Part A Arshad M. Khanani, MD, MA |
| 12:10 | Suprachoroidal RGX-314 Gene Therapy for Diabetic Retinopathy Michael A. Klufas, MD |
| 12:20 | Intact Perifoveal Capillaries Confirmed by OCT-Angiography Leads to Successful Anti-VEGF Treatment for Diabetic Macular Edema and Branch Retinal Vein Occlusion Toshinori Murata, MD, PhD |
| 12:30 | How Extent of DRSS Response Affects Outcomes in Aflibercept-Treated Eyes Within PANORAMA Diana V. Do, MD |
| 12:40 | 52-week Results from KINGFISHER, a Phase III Study with q4w Dosing of Brolucizumab 6 mg in DME Mark R. Barakat, MD |
| 12:50 | Brolucizumab for the Treatment of DME: 100-Week Results from the Two Pivotal Phase III KESTREL and KITE Studies Carl D. Regillo, MD |
| Session X: Retinal and Choroidal Vasculopathies and Degenerations Moderators: Philip J. Rosenfeld, MD, PhD; Audina M. Berrocal, MD; and Stephen G. Schwartz, MD, MBA Panelists: Byron L. Lam, MD; Richard F. Spaide, MD; Darius M. Moshfeghi, MD; Carel B. Hoyng, MD; Quan Dong Nguyen, MD, MSc; Martin Friedlander, MD, PhD; and Prashanth G. Iyer, MD, MPH |
|
| 1:00 | What's New with MacTel2 Martin Friedlander, MD, PhD |
| 1:10 | Overview of Venous Overload Choroidopathy Richard F. Spaide, MD |
| 1:20 | Aflibercept for Retinopathy of Prematurity: Firefleye Trial Darius M. Moshfeghi, MD |
| 1:30 | Bruch's Membrane and Choriocapillaris Imaging in Sorsby Macular Dystrophy Prashanth G. Iyer, MD, MPH |
| 1:40 | Stargardt Disease, Towards Therapy Carel B. Hoyng, MD |
| 1:50 | Tinlarebant, an RBP4 (Retinol Binding Protein 4) Antagonist, for Stargardt Disease Quan Dong Nguyen, MD, MSc |
| 2:00 | Treatment Update for Inherited Retinal Degenerations Byron L. Lam, MD |
| 2:10 | Post-Program Test and Closing Remarks |